华鲁品牌怎么样 申请店铺

外推网助力华鲁品牌出海！通过在本页面挂载华鲁品牌的产品链接和联系邮箱，可以提高华鲁产品曝光！跨境电商爆单神器，目前只要100元/年哦~

山东华鲁制药有限公司是一家以大输液制剂生产为主导，集科、工、贸为一体的大型综合制药企业。公司现有员工2000多人，具备生产大输液、水针剂、胶囊剂、片剂、颗粒剂、原料药六大剂型200多个规格品种药品的生产能力，公司生产规模、技术水平、品牌影响力位居国内同行业前列，是中国输液行业中品种最全和包装形式最完备的药品制造企业之一。

多年来，华鲁人始终秉承“精心做药、造福人类”的企业宗旨，视质量为生命，严格按GMP要求组织生产，树立售前、售中和售后服务意识，以优良的产品质量打造了过硬的华鲁品牌，企业的社会知名度和美誉度一路攀升。公司紧紧把握世界医药发展脉搏，把尖端技术与先进管理思想有机的融合，加大新产品研发投入，加快技术创新步伐，大胆采用新技术、新设施，促进制药产业升级换代。公司新建的高新技术产业园，总投资近6亿元，占地45万平方米，先后引进国际最先进输液生产的全自控设备，通过全程自动化传输系统的超强链接，使整个生产过程从原料投入到产品出库环环紧扣，真正实现全程自动化，将企业的生产能力与效率提升到了一个全新的高度，全力打造了一个低成本、低能耗、无污染的具有国际水准的国内输液行业绿色生产示范园区。

面对激烈的医药市场竞争，公司及时调整产品结构，努力开拓市场，公司大输液生产涵盖玻璃瓶、PP塑料瓶、非PVC多层共挤膜软袋等多种包装形式的输液产品，产品涉及心脑血管用药、抗肿瘤药、抗感染药、消化系统用药等，主要研制开发了奥扎格雷钠氯化钠注射液、替加氟氯化钠注射液、多索茶碱葡萄糖注射液、甘油果糖注射液、前列安通及吗替麦考酚酯胶囊等一批极具市场发展潜力的拳头产品，备受市场推崇。同时以胃复胶馕、胃复片为主的中药口服制剂，是公司开发新产品、形成效益增长点的又一优势。凭借先进的生产技术和可靠的产品质量，华鲁药品已覆盖全国30多个省、市、自治区，并已经走出国门，销往东南亚多个国家和地区。

华鲁制药将充分利用完善的市场销售网络，发挥公司在输液行业已形成的技术优势、品牌优势、产品体系优势、质量优势、原材料供应优势和强大的研发能力，以现有生产和产品为基础，继续调整和优化产品结构，进一步提升公司在国内输液行业的市场占有率；同时积极寻找新的规模、利润增长点，不断增强公司的竞争实力，力争到2015年实现产品销售收入20亿元，实现利税4亿元，投资3.46亿元，完成4条进口双管双阀软包装输液生产线、原料制剂车间的建设，企业总资产达到11亿元，达到年产输液产品12亿瓶，针剂8亿支，胶囊2亿粒的生产能力，成为中国医药行业规模最大、品规最全、盈利水平最高、竞争力最强的医药制造企业之一。

Shandong Hualu Pharmaceutical Co., Ltd. is a large-scale comprehensive pharmaceutical enterprise, which is led by the production of large infusion preparations and integrates science, industry and trade. With more than 2000 employees, the company has the production capacity to produce more than 200 specifications of six dosage forms of large infusion, water injection, capsule, tablet, granule and API. The production scale, technical level and brand influence of the company rank in the forefront of the same industry in China, and it is one of the pharmaceutical manufacturers with the most complete varieties and packaging forms in the infusion industry in China. Over the years, Hualu people have always adhered to the enterprise tenet of "meticulously making medicine and benefiting mankind", regarded quality as life, organized production in strict accordance with GMP requirements, established the awareness of pre-sale, sale and after-sale service, and built an excellent Hualu brand with excellent product quality. The social popularity and reputation of the enterprise have been rising all the way. The company firmly grasps the pulse of the world's pharmaceutical development, organically integrates the cutting-edge technology and advanced management ideas, increases the investment in new product research and development, speeds up the pace of technological innovation, boldly adopts new technologies and facilities, and promotes the upgrading of the pharmaceutical industry. The company's new high-tech industrial park, with a total investment of nearly 600 million yuan and an area of 450000 square meters, has successively introduced the most advanced automatic control equipment for infusion production in the world. Through the strong link of the whole process automatic transmission system, the whole production process is closely linked from raw material input to product delivery, truly realizing the whole process automation, and improving the production capacity and efficiency of the enterprise to a new one We have made every effort to build a green production demonstration park with low cost, low energy consumption and no pollution, which is of international standard in the domestic infusion industry. In the face of fierce competition in the pharmaceutical market, the company adjusted the product structure in time and made great efforts to open up the market. The company's large-scale infusion production covers glass bottles, PP plastic bottles, non PVC multi-layer coextrusion film soft bags and many other packaging forms of infusion products. The products involve cardiovascular and cerebrovascular drugs, anti-tumor drugs, anti infective drugs, digestive system drugs, etc. the main research and development is the injection of ozagrel sodium and sodium chloride Liquid, tegafur and sodium chloride injection, doxofylline and glucose injection, glycerin and fructose injection, Qianlie Antong and motimecorol ester capsule are a batch of fist products with great market development potential, which are highly praised by the market. At the same time, the oral preparation of traditional Chinese medicine, which is mainly composed of Weifu Jiaonang and Weifu tablets, is another advantage of the company in developing new products and forming benefit growth points. With advanced production technology and reliable product quality, Hualu pharmaceutical has covered more than 30 provinces, cities and autonomous regions in China, and has been exported to Southeast Asian countries and regions. Hualu pharmaceutical will make full use of the perfect market sales network, give full play to the company's formed technical advantages, brand advantages, product system advantages, quality advantages, raw material supply advantages and strong R & D capabilities in the infusion industry, continue to adjust and optimize the product structure based on the existing production and products, and further improve the company's market share in the domestic infusion industry; the same as The company actively seeks for new scale and profit growth points, and constantly strengthens the company's competitive strength. By 2015, the company strives to achieve product sales revenue of 2 billion yuan, profit and tax of 400 million yuan, investment of 346 million yuan, and complete the construction of four imported double tube and double valve soft packaging infusion production lines and raw material preparation workshops. The total assets of the company reach 1.1 billion yuan, reaching an annual output of 1.2 billion bottles of infusion products, 800 million injections and rubber With a production capacity of 200 million capsules, it has become one of the pharmaceutical manufacturing enterprises with the largest scale, the most complete product specifications, the highest profit level and the strongest competitiveness in China's pharmaceutical industry.

本文链接： https://brand.waitui.com/6acfd3c53.html 联系电话：请联系客服添加